Pages that link to "Q39655848"
Jump to navigation
Jump to search
The following pages link to T cells expressing constitutively active Akt resist multiple tumor-associated inhibitory mechanisms. (Q39655848):
Displaying 38 items.
- Breaking Free of Control: How Conventional T Cells Overcome Regulatory T Cell Suppression (Q26744624) (← links)
- Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors (Q26778759) (← links)
- CAR T cells for solid tumors: armed and ready to go? (Q26825489) (← links)
- The Role of Animal Models in the Study of Hematopoietic Stem Cell Transplantation and GvHD: A Historical Overview (Q28066083) (← links)
- T Cells Deficient in the Tyrosine Phosphatase SHP-1 Resist Suppression by Regulatory T Cells (Q30252330) (← links)
- CAR-modified T-cell therapy for cancer: an updated review. (Q34044213) (← links)
- Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumors (Q34052580) (← links)
- Selective inhibition of regulatory T cells by targeting the PI3K-Akt pathway. (Q34458364) (← links)
- Neuroblastoma: developmental biology, cancer genomics and immunotherapy (Q35283020) (← links)
- Combining mTor inhibitors with rapamycin-resistant T cells: a two-pronged approach to tumor elimination (Q35623465) (← links)
- Over-expressing Akt in T cells to resist tumor immunosuppression and increase anti-tumor activity (Q35756547) (← links)
- Genetically modified T-cell therapy for osteosarcoma (Q36198232) (← links)
- Genetic modification of human T lymphocytes for the treatment of hematologic malignancies (Q36366557) (← links)
- Immunotherapy of malignant disease using chimeric antigen receptor engrafted T cells (Q36470354) (← links)
- Comparison of naïve and central memory derived CD8(+) effector cell engraftment fitness and function following adoptive transfer (Q36597392) (← links)
- The role of E3 ubiquitin ligase Cbl proteins in interleukin-2-induced Jurkat T-cell activation (Q36754726) (← links)
- Immunology and immunotherapy of neuroblastoma (Q36856798) (← links)
- 4-cholesten-3-one suppresses lung adenocarcinoma metastasis by regulating translocation of HMGB1, HIF1α and Caveolin-1 (Q37330906) (← links)
- Design and development of therapies using chimeric antigen receptor-expressing T cells (Q37418289) (← links)
- Genetic engineering of T cells for the immunotherapy of haematological malignancies. (Q37965815) (← links)
- Gene-engineered T cells for cancer therapy (Q38123667) (← links)
- Advances in chimeric antigen receptor immunotherapy for neuroblastoma (Q38170885) (← links)
- Genetically modified T cells to target glioblastoma (Q38178690) (← links)
- CD28z CARs and armored CARs (Q38199347) (← links)
- Chimeric antigen receptors and bispecific antibodies to retarget T cells in pediatric oncology (Q38400420) (← links)
- Overcoming intrinsic inhibitory pathways to augment the antineoplastic activity of adoptively transferred T cells: Re-tuning your CAR before hitting a rocky road (Q38441750) (← links)
- Enhancing the efficacy of adoptive cellular therapy by targeting tumor-induced immunosuppression (Q38525024) (← links)
- The pharmacology of second-generation chimeric antigen receptors. (Q38541019) (← links)
- Chimeric antigen receptors for treatment of glioblastoma: a practical review of challenges and ways to overcome them (Q38987239) (← links)
- Bispecific antibody does not induce T-cell death mediated by chimeric antigen receptor against disialoganglioside GD2. (Q41033228) (← links)
- Neuroblastoma Arginase Activity Creates an Immunosuppressive Microenvironment That Impairs Autologous and Engineered Immunity. (Q41686071) (← links)
- Enhanced antitumor activity mediated by human 4-1BB-engineered T cells (Q45441936) (← links)
- CAR-T cells and combination therapies: What's next in the immunotherapy revolution? (Q47285613) (← links)
- New Approaches in CAR-T Cell Immunotherapy for Breast Cancer. (Q47761448) (← links)
- Cell death-based treatment of neuroblastoma (Q47839039) (← links)
- Chimeric antigen receptors designed to overcome transforming growth factor-β-mediated repression in the adoptive T-cell therapy of solid tumors. (Q64882079) (← links)
- Constitutively active MyD88/CD40 costimulation enhances expansion and efficacy of chimeric antigen receptor T cells targeting hematological malignancies (Q91997642) (← links)
- Targeting TGFβ signal transduction for cancer therapy (Q104795035) (← links)